Research from Redeye, Redeye AB

Redeye

Research from Redeye

Redeye AB

Specialists in innovative and fast-growing Nordic companies within Life Science and Technology.

Redeye is the next generation equity research and investment banking company, specialized in Life Science and Technology. We are the leading provider of Corporate Broking and Corporate Finance in these sectors.

Our clients are innovative growth companies in the Nordics and we use a unique Rating model based on a value based investment philosophy. Redeye was founded 1999 in Stockholm and is regulated by the Swedish Financial Authority (Finansinspektionen).

Equity Bottom-Up

<ul><li>Yesterday evening, it was announced that Ascelia had raised around SEK30m in a directed share issue - we see this as a sign of strength and give our initial take.</li></ul>

Yesterday evening, it was announced that Ascelia had raised around SEK30m in a directed share issue - we see this as a sign of strength and give our initial take.

Ascelia Pharma: SEK30m raised in a Directed Share Issue

<ul><li>Ascelia has now submitted Orviglance to the FDA.</li><li>The next step is to start the initial filing review process with an FDA confirmation within 74 days from submission.</li></ul>

Ascelia has now submitted Orviglance to the FDA.The next step is to start the initial filing review process with an FDA confirmation within 74 days from submission.

Ascelia Pharma: A timely FDA submission with an extended cash runway

<ul><li>Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September.</li><li>The second critical value driver is to secure a US partner for the upcoming launch.</li></ul>

Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early September.The second critical value driver is to secure a US partner for the upcoming launch.

Ascelia Pharma: Just about to submit Orviglance for US approval

<ul><li>Ascelia can point to considerable professional interest and confirmed scientific support ahead of the pivotal readout and the subsequent launch.</li></ul>

Ascelia can point to considerable professional interest and confirmed scientific support ahead of the pivotal readout and the subsequent launch.

Ascelia Q1: Professional interest and scientific support ahead of launch

Sweden

Ascelia Pharma AB operates as a drug development company. The Company develops medicines and drugs for the treatment of liver metastases and gastric cancer. Ascelia Pharma serves patients in Sweden.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Ascelia Pharma (ACE SS)

Ascelia Pharma: A timely FDA submission with an extended cash runway

Ascelia has now submitted Orviglance to the FDA. The next step is to start the initial filing review process with an FDA confirmation within 74...

Redeye

Ascelia Pharma: Just about to submit Orviglance for US approval

Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early...

Redeye

Ascelia Q1: Professional interest and scientific support ahead of launch

Ascelia can point to considerable professional interest and confirmed scientific support ahead of the pivotal readout and the subsequent launch.

Redeye

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Ascelia Pharma: SEK30m raised in a Directed Share Issue

Yesterday evening, it was announced that Ascelia had raised around SEK30m in a directed share issue - we see this as a sign of strength and give...

Redeye

Ascelia Pharma: A timely FDA submission with an extended cash runway

Ascelia has now submitted Orviglance to the FDA. The next step is to start the initial filing review process with an FDA confirmation within 74...

Redeye

Ascelia Pharma: Just about to submit Orviglance for US approval

Ascelia’s two most important value drivers are the US submission, which is now de-risked, and Ascelia is expecting a submission in early...

Redeye

Ascelia Q1: Professional interest and scientific support ahead of launch

Ascelia can point to considerable professional interest and confirmed scientific support ahead of the pivotal readout and the subsequent launch.

Redeye